Shots: The US FDA approved FoundationOneCDx to be used as a CDx for Vitrakvi (larotrectinib) to identify patients with NTRK fusions across all solid tumors. The genomic test is currently […]readmore
Tags : Solid
Shots: The companies collaborate to conduct P-I/II clinical trial assessing CyPep-1 in patients to treat advanced solid cancers. SMS-Oncology will focus on developing protocol and giving guidance on patient inclusion […]readmore